Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …

Clinical questions What is the role of plasma exchange and what is the optimal dose of
glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic …

Background: Ear, nose and throat (ENT) manifestations are common in patients with
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), yet how to treat …

Background: Different types of inflammatory processes and fibrosis have been implicated in
the pathogenesis of interstitial lung disease (ILD), a heterogeneous, diffuse, parenchymal …

Introduction Managing complex and rare systemic autoimmune diseases such as
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) can be challenging …

Objectives Diagnosing patients with ANCA-associated vasculitis (AAV) can be challenging
owing to its rarity and complexity. Diagnostic delay can have severe consequences, such as …

Background: Renal involvement in patients with anti-neutrophil cytoplasmic antibody
(ANCA) associated vasculitis (AAV) often presents as acute kidney injury (AKI), which is …

Background Acute exacerbation (AE) is a life-threatening condition taking place not only in
idiopathic pulmonary fibrosis (IPF) but also in interstitial lung diseases (ILD) other than IPF …

Giant cell arteritis (GCA) and anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) are diseases marked by inflammation of blood vessels. Vascular damage …

Objectives. Diagnosing patients with ANCA-associated vasculitis (AAV) can be challenging
owing to its rarity and complexity. Diagnostic delay can have severe consequences, such as …